Dr. Frank Yocca is an accomplished R&D executive and scientist with extensive experience leading global biopharmaceutical companies. He has wide-ranging expertise in leading high-performing, world-class teams in drug discovery and development whose efforts have resulted in a number of prominent neuroscience products including Buspar®, Serzone® Abilify®, and Heltioz®. Frank has held leadership roles at AstraZeneca and Bristol Myers Squibb. He is a recognized scientific leader in the neuroscience community, a member of the Institute of Medicine of the National Academy of Science, and a Fellow of the American College of Neuropsychopharmacology. He has 45 referred articles, 96 abstracts, and 65 invited presentations.  In 2023, the Healthcare Technology Report listed him among the top healthcare technology leaders of Connecticut. 

Dr. Yocca holds a B.S. in Biochemistry from Manhattan College, as well as an M.S. in Pharmacology and a Ph.D. in Neuropharmacology from St. John’s University.